PTH and secondary hyperparathyroidism: The trial titled “Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE)” showed a non-significant 7% reduction in the risk of death with the use of cinacalcet to lower PTH level in patients with moderate to severe secondary hyperparathyroidism [38].